<div id="readability-page-1"><p>Nekton Capital Ltd. bought a new position in shares of  Enfusion, Inc. (NYSE:ENFN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 43,611 shares of the company's stock, valued at approximately $449,000. Enfusion makes up  approximately  1.2% of Nekton Capital Ltd.'s investment portfolio, making the stock its 7th largest holding.</p><p>A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in  Enfusion during the fourth quarter valued at approximately $75,000.  Tower Research Capital LLC TRC boosted its stake in shares of  Enfusion by 58.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company's stock worth $136,000 after acquiring an additional 4,889 shares in the last quarter.  Quantbot Technologies LP acquired a new position in shares of  Enfusion in the 4th quarter worth $144,000.  Intech Investment Management LLC acquired a new stake in shares of  Enfusion during the fourth quarter worth $191,000.  Finally, Wells Fargo &amp; Company MN lifted its holdings in shares of  Enfusion by 46.8% during the fourth quarter. Wells Fargo &amp; Company MN now owns 25,499 shares of the company's stock valued at $263,000 after purchasing an additional 8,126 shares during the last quarter. 81.05% of the stock is owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several analysts have issued reports on ENFN shares. Piper Sandler boosted their price objective on Enfusion from $10.00 to $11.50 and gave the stock a &#34;neutral&#34; rating in a report on Monday, December 23rd. William Blair  restated a &#34;market perform&#34; rating on shares of Enfusion in a report on Monday, January 13th.</p><p><b>Get Our Latest Report on ENFN</b></p><h2>Insider Buying and Selling at Enfusion</h2><p>In related news, COO Neal Pawar sold 2,769 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the sale, the chief operating officer now owns 1,231,627 shares of the company's stock, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Oleg Movchan sold 2,790 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $32,029.20. Following the completion of the transaction, the chief executive officer now owns 643,299 shares in the company, valued at $7,385,072.52. This represents a 0.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,223 shares of company stock valued at $754,778 in the last quarter. Company insiders own  36.44% of the company's stock. </p><h2>Enfusion Trading Up 0.5 %</h2><p>Shares of ENFN stock opened at $10.85 on Tuesday. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 271.29, a P/E/G ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80. The stock's fifty day simple moving average is $11.07 and its 200-day simple moving average is $10.44. </p><p>Enfusion (NYSE:ENFN - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The business had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million.  On average, sell-side analysts predict that  Enfusion, Inc. will post 0.06 EPS for the current year. </p><h2>About Enfusion</h2> (Free Report)<p>Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.</p><h2>Read More</h2><ul><li>Five stocks we like better than Enfusion</li><li>How to Short Nasdaq: An Easy-to-Follow Guide</li><li>AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock</li><li>The Basics of Support and  Resistance</li><li>Why Call Option Traders Are Targeting This Dividend ETF Now</li><li>What is the Nikkei 225 index?    </li><li>Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying</li></ul><p><strong>Want to see what other hedge funds are holding ENFN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVORk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVORk4"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Enfusion Right Now?</h2><p>Before you consider Enfusion, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.</p><p>While Enfusion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ENFN

<p>Nekton Capital Ltd. acquired 43,611 shares of Enfusion, Inc. (NYSE:ENFN) valued at approximately $449,000 during Q4, making it the 7th largest holding in their portfolio. Other institutional investors also increased their stakes. Analysts have raised price targets for ENFN, with Piper Sandler setting it at $11.50. Enfusion reported a Q4 EPS of $0.01, missing estimates, with revenue of $52.94 million. The stock opened at $10.85, with a market cap of $1.40 billion and a P/E ratio of 271.29.</p>

Nekton Capital Ltd. Takes Position in Enfusion, Inc. (NYSE:ENFN)